In vitro HIV-specific CTL activity from HIV-seropositive individuals is augmented by interleukin-12 (IL-12)

AIDS Research and Human Retroviruses

Volumn 17, Issue 3, 2001, Pages 233-242

  Young, J M ^a   Ffrench, R A ^a   Clarkson, J D ^a   Stewart, G J ^a   Liang, T ^a   Tideman, R L ^a   Packham, D ^a   Fulher, D A ^a   Benson, E M ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; IMMUNOMODULATING AGENT; INTERLEUKIN 12; POL PROTEIN; RECOMBINANT INTERLEUKIN 12;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOMODULATION; MALE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL;

ADULT; CELLS, CULTURED; FEMALE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HUMANS; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 0035835509     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201750063151     Document Type: Article

References (47)

1. The art of 'HAART': Researchers probe the potential and limits of aggressive HIV treatments
2. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
3. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CDS+ lymphocyte activity
4. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type I infection
5. Human immunodeficiency virus type 1- and cytomegalovirus-specific cytotoxic T lymphocytes can persist at high frequency for prolonged periods in the absence of circulating peripheral CD4(+) T cells
6. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type I syndrome
7. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
8. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
9. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells
10. Vigorous HIV-1-specific CD4+ T cells responses associated with control of viremia
11. Function and clinical use of IL-12
12. In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS)
13. Priming for high interferon γ production induced by interleukin-12 in both CD4+ and CD8+ clones from HIV-infected patients
14. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients
15. Interleukin-12 enhancement of antigen-specific lymphocyte proliferation correlates with stage of human immunodeficiency virus infection
16. In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type I
17. Natural killer cell stimulatory factor (interleukin-12 [IL-12]) induces T helper type I (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells
18. IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL)
19. IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro
20. In vitro effects of IL-12 on HIV-1 specific CTL lines from HIV-1-infected children
21. Impaired interleukin 12 production in human immunodeficiency virus-infected patients
22. The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals
23. Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus
24. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides
25. Limiting dilution analysis of precursors of cytotoxic T lymphocytes
26. Selective in vitro expansion of HLA class I-restricted HIV-1 gag-specific CD8+ T cells: Cytotoxic T-lymphocyte epitopes and precursor frequencies
27. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor)
28. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-αβ+, TCR-γδ T lymphocytes, and NK cells
29. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens
30. Phenotypic characterisation of CDS+ T cell populations in HIV disease and in anti-HIV immunity
31. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes
32. Analysis of the human env-specific cytotoxic T-lymphocyte (CTL) response in natural human immunodeficiency virus type 1 infection: Low prevalence of broadly cross-reactive env-specific CTL
33. The immune response to HIV: Potential for immunotherapy
34. Cytokines and impaired CD8+ CTL activity among elderly persons and the enhanceing effect of IL-12
35. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines
36. Quantitative analysis of the human immunodeficiency virus type I (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
37. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans
38. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: In vitro quantitation of effector cell populations with p17 and p24
39. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors
40. Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors
41. Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men
42. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: Evidence supporting a protective role for CTL in vivo
43. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression
44. Functional characterisation and modulation of cytokine production by CD8+ T cells from human immunodeficiency virus-infected individuals
45. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals
46. Effects of Th1 and Th2 cytokines on CD8+ cell response against human immunodeficiency virus: Implications for long-term survival
47. Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells